Commissioner Expects Pandemic Response To Continue Steering US FDA Decisions, Priorities
Executive Summary
FDA faces unprecedented challenges responding to pandemic, needing to balance urgency, speed, safety and transparency against a fast-moving background. Hahn, who spoke at a recent medical device industry conference and will testify at a congressional hearing on 23 June, says he has focused on making decisions supported by data and science, and updating those decisions as more information became available.
You may also be interested in...
Trump’s Latest COVID-19 Remedy Suggestion Spurs Quick Rebuke From Experts
Trade groups and botanical experts, perhaps erring on the side of choosing not to ignore yet another groundless health care claim by the president, quickly published alerts that all parts of the oleander plant are poisonous if consumed by humans.
False COVID-19 Claims In US Consumer Health Market: Rampant With Forecast For More
In addition to 45 businesses with varying levels of communication skills the FTC targeted in its latest batch of warnings about false advertising linked coronavirus, the FDA "sent hundreds of abuse complaints to domain name registrars and internet marketplaces" also linked to bogus COVID-19 claims.
Federal Agencies Shut Down Church Group's Sales Of Bleach Mixture Promoted As COVID-19 Cure
The combination of Genesis II Church's rejection of FDA's warning, the potential for serious adverse events linked to its chlorine dioxide formulation and its claims the product treats COVID-19 led FDA to seek an injunction to stop sales of the product a week after it warned the group.